Compound ID | 626
Class: Beta-lactam (monobactam)
| Spectrum of activity: | Gram-positive |
| Details of activity: | Potent against Gram negatives, was intended to go into clinical trials for Pseudomonas infections. |
| Institute where first reported: | PanTherix Ltd, UK (Licensed); Naeja Pharmaceutical Inc, Canada (Ceased R&D) |
| Year first mentioned: | 2003 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | PanTherix couldn't raise $15 million to take this further (1) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/129846797 |
| Citations: |
|